Arends T, Hamm D, van der Maarel S, Tapscott S
Cold Spring Harb Perspect Biol. 2024; .
PMID: 39009417
PMC: 11733064.
DOI: 10.1101/cshperspect.a041492.
Shim Y, Seo J, Lee S, Choi J, Choi Y, Shin S
Ann Lab Med. 2024; 44(5):437-445.
PMID: 38724225
PMC: 11169776.
DOI: 10.3343/alm.2023.0437.
Jiang J, Cai X, Qu H, Yao Q, He T, Yang M
Front Neurol. 2024; 15:1258831.
PMID: 38361638
PMC: 10867183.
DOI: 10.3389/fneur.2024.1258831.
Nunes A, Ramirez M, Garcia-Collazo E, Jones T, Jones P
Hum Mol Genet. 2024; 33(10):872-883.
PMID: 38340007
PMC: 11070135.
DOI: 10.1093/hmg/ddae019.
Runfola V, Giambruno R, Caronni C, Pannese M, Andolfo A, Gabellini D
Cell Rep. 2023; 42(9):113120.
PMID: 37703175
PMC: 10591880.
DOI: 10.1016/j.celrep.2023.113120.
Nutritional Status of Patients with Facioscapulohumeral Muscular Dystrophy.
Amzali S, Wilson V, Bommart S, Picot M, Galas S, Mercier J
Nutrients. 2023; 15(7).
PMID: 37049513
PMC: 10096775.
DOI: 10.3390/nu15071673.
Management of scapular dysfunction in facioscapulohumeral muscular dystrophy: the biomechanics of winging, arthrodesis indications, techniques and outcomes.
Eren I, Gedik C, Kilic U, Abay B, Birsel O, Demirhan M
EFORT Open Rev. 2022; 7(11):734-746.
PMID: 36475552
PMC: 9780611.
DOI: 10.1530/EOR-22-0080.
Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A, Lassche S, Mul K, Greco A, San Leon Granado D, Heerschap A
Sci Rep. 2022; 12(1):1426.
PMID: 35082321
PMC: 8791933.
DOI: 10.1038/s41598-022-04817-8.
Prevalence and disease progression of genetically-confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide population-based study.
Wang Z, Qiu L, Lin M, Chen L, Zheng F, Lin L
Lancet Reg Health West Pac. 2022; 18:100323.
PMID: 35024656
PMC: 8671729.
DOI: 10.1016/j.lanwpc.2021.100323.
Upper Limb Rehabilitation in Facioscapulohumeral Muscular Dystrophy: A Patients' Perspective.
Faux-Nightingale A, Kulshrestha R, Emery N, Pandyan A, Willis T, Philp F
Arch Rehabil Res Clin Transl. 2022; 3(4):100157.
PMID: 34977539
PMC: 8683863.
DOI: 10.1016/j.arrct.2021.100157.
Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
Katz N, Hogan J, Delbango R, Cernik C, Tawil R, Statland J
Brain. 2021; 144(11):3451-3460.
PMID: 34542603
PMC: 8677548.
DOI: 10.1093/brain/awab326.
Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes A, Ramirez M, Jones T, Jones P
Dis Model Mech. 2021; 14(8).
PMID: 34338285
PMC: 8405850.
DOI: 10.1242/dmm.049016.
Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones T, Chew G, Barraza-Flores P, Schreier S, Ramirez M, Wuebbles R
Skelet Muscle. 2020; 10(1):8.
PMID: 32278354
PMC: 7149937.
DOI: 10.1186/s13395-020-00227-4.
Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
Greco A, Goossens R, van Engelen B, van der Maarel S
Clin Genet. 2020; 97(6):799-814.
PMID: 32086799
PMC: 7318180.
DOI: 10.1111/cge.13726.
Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy (FSHD).
Dai Y, Li P, Wang Z, Liang F, Yang F, Fang L
J Med Genet. 2019; 57(2):109-120.
PMID: 31506324
PMC: 7029236.
DOI: 10.1136/jmedgenet-2019-106078.
Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J, Galasinski S, Richey A, Campbell A, Meyers M, Modi N
J Pharmacol Exp Ther. 2019; 370(2):219-230.
PMID: 31189728
PMC: 6652132.
DOI: 10.1124/jpet.119.259663.
A Pediatric Review of Facioscapulohumeral Muscular Dystrophy.
Mah J, Chen Y
J Pediatr Neurol. 2019; 16(4):222-231.
PMID: 30923442
PMC: 6435288.
DOI: 10.1055/s-0037-1604197.
Genotype-phenotype correlations in FSHD.
Zernov N, Skoblov M
BMC Med Genomics. 2019; 12(Suppl 2):43.
PMID: 30871534
PMC: 6416831.
DOI: 10.1186/s12920-019-0488-5.
Histone Modifications and the Maintenance of Telomere Integrity.
Jezek M, Green E
Cells. 2019; 8(2).
PMID: 30823596
PMC: 6407025.
DOI: 10.3390/cells8020199.
A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1.
Wohlgemuth M, Lemmers R, Jonker M, van der Kooi E, Horlings C, van Engelen B
Neurology. 2018; 91(5):e444-e454.
PMID: 29997197
PMC: 6093768.
DOI: 10.1212/WNL.0000000000005915.